Sarcoidosis secondary to lymphocyte active immunotherapy treated with infliximab*
Lido
5441
Vezesque se leu este artigo
2538
Total PDF
2903
Total HTML
| Ano/Mês | Html | Total | |
|---|---|---|---|
| 2025 6 | 23 | 17 | 40 |
| 2025 5 | 132 | 55 | 187 |
| 2025 4 | 110 | 39 | 149 |
| 2025 3 | 134 | 34 | 168 |
| 2025 2 | 129 | 80 | 209 |
| 2025 1 | 118 | 55 | 173 |
| 2024 12 | 73 | 42 | 115 |
| 2024 11 | 106 | 48 | 154 |
| 2024 10 | 90 | 70 | 160 |
| 2024 9 | 130 | 77 | 207 |
| 2024 8 | 138 | 87 | 225 |
| 2024 7 | 133 | 120 | 253 |
| 2024 6 | 117 | 80 | 197 |
| 2024 5 | 133 | 56 | 189 |
| 2024 4 | 78 | 63 | 141 |
| 2024 3 | 52 | 65 | 117 |
| 2024 2 | 65 | 77 | 142 |
| 2024 1 | 50 | 54 | 104 |
| 2023 12 | 31 | 56 | 87 |
| 2023 11 | 39 | 60 | 99 |
| 2023 10 | 39 | 43 | 82 |
| 2023 9 | 39 | 59 | 98 |
| 2023 8 | 31 | 25 | 56 |
| 2023 7 | 37 | 43 | 80 |
| 2023 6 | 46 | 41 | 87 |
| 2023 5 | 33 | 29 | 62 |
| 2023 4 | 35 | 30 | 65 |
| 2023 3 | 26 | 27 | 53 |
| 2023 2 | 26 | 34 | 60 |
| 2023 1 | 31 | 22 | 53 |
| 2022 12 | 29 | 22 | 51 |
| 2022 11 | 31 | 36 | 67 |
| 2022 10 | 49 | 28 | 77 |
| 2022 9 | 23 | 57 | 80 |
| 2022 8 | 39 | 39 | 78 |
| 2022 7 | 26 | 36 | 62 |
| 2022 6 | 37 | 43 | 80 |
| 2022 5 | 27 | 42 | 69 |
| 2022 4 | 21 | 36 | 57 |
| 2022 3 | 23 | 45 | 68 |
| 2022 2 | 16 | 27 | 43 |
| 2021 1 | 38 | 54 | 92 |
| 2021 12 | 34 | 50 | 84 |
| 2021 11 | 30 | 54 | 84 |
| 2021 10 | 36 | 60 | 96 |
| 2021 9 | 22 | 38 | 60 |
| 2021 8 | 20 | 30 | 50 |
| 2021 7 | 17 | 33 | 50 |
| 2021 6 | 14 | 36 | 50 |
| 2021 5 | 35 | 40 | 75 |
| 2021 4 | 57 | 123 | 180 |
| 2021 3 | 15 | 10 | 25 |
| 2021 2 | 14 | 7 | 21 |
| 2020 1 | 18 | 0 | 18 |
| 2020 12 | 8 | 4 | 12 |
Mostrar tudo
